Unit of Pharmacology, Tuscan Regional Center of Pharmacovigilance, University Hospital of Pisa, and Department of Internal Medicine, Interdepartmental Center of Research in Clinical Pharmacology and Experimental Therapeutics, University of Pisa, Pisa, Italy.
Dermatology. 2012;224(3):212-4. doi: 10.1159/000337412. Epub 2012 May 11.
We describe two cases of telogen effluvium occurring in two 11-year-old children following bivalent human papillomavirus (HPV) vaccine administration. The two children began to lose their hair following the second HPV vaccine dose. Alopecia worsened following the third vaccine dose and then resolved spontaneously within a few months. In both cases, laboratory analysis and psychiatric evaluation excluded causes other than anti-HPV vaccine. Social discomfort and isolation were associated with alopecia in the two children. The clinical presentation was consistent with a pattern of telogen effluvium. The identification of specific vaccine components responsible for triggering the adverse event remains difficult. In similar cases, suspension of immunization is not recommended, as it provides health benefits that overcome the possible adverse effect of transient telogen effluvium. Caregivers should ensure psychiatric support to their patients to manage the social and emotional distress that might be associated with hair loss.
我们描述了两例 11 岁儿童在接种二价人乳头瘤病毒(HPV)疫苗后发生休止期脱发的病例。这两个孩子在接种第二针 HPV 疫苗后开始脱发。脱发在接种第三针疫苗后加重,然后在几个月内自发缓解。在这两种情况下,实验室分析和精神科评估排除了除抗 HPV 疫苗以外的其他原因。脱发使两个孩子感到社交不适和孤立。临床表现与休止期脱发一致。确定导致不良事件的特定疫苗成分仍然很困难。在类似情况下,不建议暂停免疫接种,因为其带来的健康益处超过了短暂休止期脱发的可能不良影响。护理人员应确保为患者提供精神支持,以应对可能与脱发相关的社会和情绪困扰。